18+ · Research use only
Retatrutide vs tirzepatide: the triple agonist against the dual.
Two incretin compounds, one receptor apart, separated by ₱1,675 per vial in the Philippines. The trial numbers, the peso numbers, and how research buyers choose.
One receptor apart
Tirzepatide, the compound behind Mounjaro, is a dual agonist: it acts on the GIP and GLP-1 receptors. Retatrutide takes the same scaffold logic one step further and adds the glucagon receptor, making it a triple agonist. That third target is the entire research story. Glucagon receptor activity is associated with increased energy expenditure in the literature, which is the leading explanation for why retatrutide's Phase 2 curve kept falling where earlier incretins plateaued.
The published anchors: retatrutide reported 28.3% mean weight reduction at 80 weeks in Phase 3 TRIUMPH-1, and 24.2% at 48 weeks in Phase 2 (Jastreboff et al., NEJM 2023), with TRIUMPH-1 through TRIUMPH-4 now read out and an FDA filing planned for Q1 2027. Tirzepatide reported 22.5% at 72 weeks in SURMOUNT-1 (NEJM 2022) and later beat semaglutide head-to-head in SURMOUNT-5. Different trial lengths and populations mean the two figures are not a clean head-to-head, but the direction of the field is clear: each added receptor has moved the ceiling.
The peso comparison
From local Metro Manila stock, the two sit close enough that price rarely decides the question. Retatrutide ships as a 20mg lyophilized vial and tirzepatide as a 15mg one, both with batch-numbered labels, same-day dispatch in Metro Manila for orders verified before noon, and courier nationwide.
| Compound | Receptors | Trial anchor | Price per vial |
|---|---|---|---|
| Retatrutide | GIP, GLP-1, glucagon | 28.3% at 80 weeks, Phase 3 | ₱3,775 / ₱3,390 with 10% off |
| Tirzepatide | GIP, GLP-1 | 22.5% at 72 weeks, SURMOUNT-1 | ₱2,100 / ₱1,890 with 10% off |
How buyers actually decide
In practice the decision usually comes down to two things. Research focus first: tirzepatide has the deeper published record, including a completed Phase 3 program and a head-to-head win, while retatrutide is the frontier compound whose Phase 3 data is still landing. Availability second: retatrutide 20mg is in stock, while tirzepatide 15mg is in stock alongside it. Retatrutide carries a clear premium at both price points, so cost is a real input to the decision rather than a tiebreaker. A deeper breakdown of local versus import pricing sits in the retatrutide price guide.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Retatrutide vs tirzepatide questions
Which costs more in the Philippines, retatrutide or tirzepatide?
Retatrutide 20mg lists at ₱3,775, or ₱3,390 with 10% off. Tirzepatide 15mg lists at ₱2,100, or ₱1,890 with 10% off. Retatrutide costs ₱1,675 more per vial at list, ₱1,500 more with 10% off applied.
What is the mechanistic difference between the two?
Tirzepatide is a dual agonist acting on GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, which is why the literature calls it a triple agonist.
Which has stronger published trial results?
Retatrutide reported 28.3% mean weight reduction at 80 weeks in Phase 3 TRIUMPH-1, after 24.2% at 48 weeks in Phase 2 (Jastreboff et al., NEJM 2023). Tirzepatide reported 22.5% at 72 weeks in SURMOUNT-1 (NEJM 2022). The trials differ in length and design, so direct comparison has limits, but retatrutide's curve reached further, faster.
Is tirzepatide in stock at Primara Labs?
Tirzepatide 15mg is in stock, with same-day Metro Manila dispatch on orders verified before noon. Retatrutide 20mg is in stock.